Eli Lilly agreed to acquire three vaccine companies in deals totaling up to $3.8 billion, pushing further into infectious disease prevention. The transactions include Vaccine Company Inc., Curevo, and LimmaTech Biologics, each bringing vaccine candidates and platform technology to Lilly’s pipeline. Lilly’s acquisitions add capabilities aimed at developing longer-lasting immune responses while targeting key infectious disease markets such as shingles (via a synthetic-adjuvant approach at Curevo) and bacterial pathogens (via LimmaTech’s vaccine work). Vaccine Company Inc.’s in vivo nanoparticle technology is designed to enable robust immunity with reduced manufacturing burden. The move follows Lilly’s earlier infectious disease leadership changes, including the hiring of FDA vaccine veteran Peter Marks, and arrives amid a wider pharma M&A push into clinical-stage platforms. For biotech investors, the deals reinforce that big-pharma capital is still flowing toward immunology-adjacent platform assets where late-stage data and manufacturing differentiation can shorten time to clinical impact.